Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Regeneron Pharmaceuticals
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07626411CT.gov Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | — | Not Yet Recruiting | — | — | — |
NCT07430956CT.gov Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | — | Recruiting | — | — | — |
NCT07175428CT.gov Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Atrial Fibrillation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cenvacibart (this asset) | Regeneron Pharmaceuticals | P3 | BB · 66 |
| Edoxaban | National Taiwan University Hospital | P4 | A |
| Rivaroxaban | VA Office of Research and Development | P4 | BBB |
| Dabigatran | Pfizer | P4 | BBB |
| Warfarin | Pfizer | P4 | BBB |
| Apixaban | Regeneron Pharmaceuticals | P4 | BBB |
| Aspirin | Yonsei University | P4 | BBB |
| 3-(.ALPHA.-ACETONYL-P-NITROBENZYL)-4-HYDROXYCOUMARIN | University of Edinburgh | P4 | BB |
| Tirzepatide | Ali Aminian | P4 | BB |
+32 more in the Atrial Fibrillation cohort
Other indications for Cenvacibart
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Venous Thromboembolism | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cenvacibart in Atrial Fibrillation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cenvacibart-atrial-fibrillation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →